logo

For the Inventor, By the Inventor

Zagreb, Croatia

Mladen Mercep

This inventor holds 16 USPTO granted patents and 1 EPO patent, primarily in Anti-Inflammatory Compounds. Top assignees: Glaxosmithkline Istrazivacki Centar Zagreb D.o.o., Pliva-Istrazivacki Institut D.o.o., Glaxosmithkline Istrazivacki Centar Zagreb. Active years: 2005-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mladen Mercep. Retrieved from https://idiyas.com/inventor/mladen-mercep

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16

 

Average Co-Inventor Count = 4.5

ph-index = 2

Forward Citations = 43(Granted Patents)


Company Filing History:

goldMedal7 out of 9 
 
Glaxosmithkline Istrazivacki Centar Zagreb D.o.o.
 patents
silverMedal4 out of 4 
 
Pliva-Istrazivacki Institut D.o.o.
 patents
bronzeMedal2 out of 2 
 
Glaxosmithkline Istrazivacki Centar Zagreb
 patents
4. 1 out of 1 
 
Glaxosmith Kline Istrazivocki Centar Zagreb, D.o.o.
 patent
5. 1 out of 2 
 
Glaxosmithkline Istrazivacki Center Zagreb D.o.o
 patents
6. 1 out of 358 
 
Glaxosmithkline LLC
 patents

Years Active: 2005-2011

Loading Chart...
Loading Chart...
Areas of Expertise:
Anti-Inflammatory
Tumor Necrosis Factor
Macrolide Compounds
Furochromenes
Dibenzoazulenes
Cellular Targeting
Steroid Carriers
Inflammatory Diseases
Nonsteroidal Substances
Compositions
Therapeutic Methods
16 patents (USPTO):Explore Patents
1. 7928078 - Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy (2011-04-19),
2. 7579334 - Compounds with anti-inflammatory activity (2009-08-25),
3. 7550498 - 1,2-Diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof (2009-06-23),
4. 7446097 - Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy (2008-11-04),
5. 7435834 - 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof (2008-10-14),
6. 7384975 - Substituted furochromenes, preparation thereof and their antiinflammatory action (2008-06-10),
7. 7312203 - 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof (2007-12-25),
8. 7262309 - 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof (2007-08-28),
9. 7262302 - 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof (2007-08-28),
10. 7232815 - 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof (2007-06-19),
11. 7208518 - Substituted furochromene compounds of antiinflammatory action (2007-04-24),
12. 7166583 - 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof (2007-01-23),
13. 7157433 - Compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules (2007-01-02),
14. 7109176 - Nonsteroidal anti-inflammatory substances, compositions and methods for their use (2006-09-19),
15. 7091187 - Compounds, compositions and methods for treatment of inflammatory diseases and conditions (2006-08-15),

Title: The Innovations of Mladen Mercep: A Pioneer in Anti-Inflammatory Research

Introduction

Mladen Mercep, a renowned inventor based in Zagreb, Croatia, has made significant contributions to the field of pharmaceutical research, specifically in the development of anti-inflammatory compounds. With a remarkable portfolio of 16 patents, his work continues to influence therapies for inflammatory diseases in both humans and animals.

Latest Patents

Among his most recent innovations, Mladen Mercep has developed groundbreaking compounds, including "Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy." This invention focuses on creating novel compounds aimed at treating inflammatory diseases, offering enhanced cellular targeting capabilities. Another notable patent is for "Compounds with anti-inflammatory activity," which introduces new compounds with distinct structures, derived from both steroidal and nonsteroidal anti-inflammatory drugs, aimed at improving therapeutic efficacy in the treatment of inflammation.

Career Highlights

Mladen’s career is marked by impactful roles in significant pharmaceutical companies. He has worked with GlaxoSmithKline Research Centre Zagreb and Pliva Research Institute, where he applied his expertise to develop innovative medicinal products. His experience in these organizations has undoubtedly played a crucial role in shaping his patent portfolio and research direction.

Collaborations

Throughout his career, Mladen has collaborated with esteemed colleagues, including Milan Mesic and Dijana Pesic. These partnerships have facilitated the exchange of ideas and knowledge, leading to advancements in their shared research endeavors and the successful development of innovative drug therapies.

Conclusion

Mladen Mercep stands out as a key figure in the innovation of anti-inflammatory treatments. With his impressive list of patents and collaboration with industry leaders, he continues to pave the way for new and effective therapies to combat inflammatory diseases, making him a vital contributor to the future of pharmaceutical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…